| Autor: |
McPherson, Tess, Cork, Michael J., Goodhead, Charlotte, Michaelis, Louise J., Flohr, Carsten, Petrovic, Milos, Hennessy, Liz, Rajkovic, Ivana, Hudson, Richard |
| Předmět: |
|
| Zdroj: |
Pediatric Dermatology; Jan/Feb2023, Vol. 40 Issue 1, p50-63, 14p |
| Abstrakt: |
Purpose: To describe secondary care health care resource utilization (HCRU) for children and adolescents with atopic dermatitis (AD). Patients and Methods: This UK chart review of patients with moderate‐to‐severe AD was conducted in four National Health Service hospitals. Cohorts were defined by age (children 6–11 years, adolescents 12–17) at first consultation. Eligible patients were selected consecutively, starting with the most recently consulting patient. At least 12 months' data were abstracted from medical records. Data were collected on HCRU, demographics/clinical characteristics, treatment, and patient‐reported outcomes. Results: Data were abstracted for 55 patients. Most patients (80%) had severe AD at first referral, a mean (SD) of 3.2 (10.7) patient‐reported flare episodes/patient/year‐of‐observation, and 18.5 (16.7) tests/scans/procedures/patient/year. Mean (SD) observation duration was 3.6 (1.8) years. Patients had tried mean (SD) 7.9 (5.3) treatments/patient/year of observation. Topical corticosteroids (TCS; 24.5% of prescriptions) were most frequently prescribed. Mean (SD) use of emollients/moisturizers, TCS, systemic corticosteroids, and systemic immunosuppressants was 30.9 (21.3), 21.1 (23.4), 1.7 (8.3), and 7.8 (8.2) months. There was a mean (SD) of 5.3 (2.9) consultations/patient/year‐of‐observation; 116 (10.7%) for flare. Most hospitalizations (87.5%) were for children; the 8/55 (15%) hospitalized patients (mean 2.0 hospitalizations/patient during observation period) spent 6.2 (SD: 5.1) nights in hospital/hospitalization. Earliest mean (SD) Children's Dermatology Life Quality Index score was 15.3 (7.2); latest was 12.9 (7.5). Conclusion: Children and adolescents with moderate‐to‐severe AD had a high HCRU burden and small changes in quality of life, indicating that current treatments may provide suboptimal AD control in most cases. [ABSTRACT FROM AUTHOR] |
| Databáze: |
Complementary Index |
| Externí odkaz: |
|
Plný text